Devil is in the details. They had a very good quarter. Projected sales of drugs Eisai sell's in the USA in 2013 they are guiding 11% decrease. How much will that be in Dacogen. If the impact is shared equally, then next year 25M less in dacogen sales. However, I'm sure the rest of the pipeline isn't being impacted with generic.
Have to look at what they sell and trends. The key, is how much of this decline next year is all Dacogen?
Last quarter they did $59M this quarter $63M. It's a shame that this couldn't continue. If somehow Dr. Reddy's doesn't launch, astex could have been looking at $4.8M in revenues increase in 2013. This would have been from eisai only and J&J growth would have been the icing on the cake.
However we have to face realities and factor in a generic.